Immunovant (IMVT) Expected to Release Quarterly Earnings on Thursday

Immunovant (NASDAQ:IMVT) is anticipated to announce its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Immunovant to announce earnings of ($0.66) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same period in the prior year, the firm posted ($0.64) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Trading Down 0.7%

NASDAQ:IMVT opened at $38.61 on Thursday. The firm’s fifty day simple moving average is $36.46 and its 200 day simple moving average is $29.98. The firm has a market capitalization of $7.97 billion, a price-to-earnings ratio of -13.89 and a beta of 0.76. Immunovant has a twelve month low of $14.32 and a twelve month high of $41.23.

Insider Activity at Immunovant

In other news, COO Melanie Gloria sold 17,714 shares of Immunovant stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $38.31, for a total value of $678,623.34. Following the transaction, the chief operating officer owned 224,393 shares of the company’s stock, valued at $8,596,495.83. The trade was a 7.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Andrew J. Fromkin sold 221,951 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $33.51, for a total value of $7,437,578.01. Following the completion of the transaction, the director directly owned 74,382 shares in the company, valued at $2,492,540.82. This represents a 74.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 327,312 shares of company stock worth $11,418,145. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Immunovant

Several large investors have recently added to or reduced their stakes in IMVT. Deep Track Capital LP lifted its stake in Immunovant by 2.4% in the 3rd quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after acquiring an additional 228,845 shares in the last quarter. Armistice Capital LLC increased its stake in shares of Immunovant by 12.2% in the third quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock worth $94,076,000 after acquiring an additional 636,000 shares during the last quarter. Morgan Stanley raised its holdings in shares of Immunovant by 147.4% during the fourth quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock worth $123,195,000 after acquiring an additional 2,887,359 shares in the last quarter. State Street Corp raised its holdings in shares of Immunovant by 30.9% during the fourth quarter. State Street Corp now owns 3,786,926 shares of the company’s stock worth $96,264,000 after acquiring an additional 894,308 shares in the last quarter. Finally, RTW Investments LP acquired a new stake in Immunovant during the fourth quarter valued at $80,781,000. 47.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IMVT has been the topic of several recent research reports. HC Wainwright boosted their price target on Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Bank of America lifted their price target on Immunovant from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Guggenheim increased their target price on shares of Immunovant from $44.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. The Goldman Sachs Group boosted their price objective on Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Finally, Citigroup boosted their target price on shares of Immunovant from $57.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.11.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.